Showing results (1-10 of 21) with videos related to
Sort By:
Pageof 3
Human Vaccines & Immunotherapeutics|July 12, 2016
What do we know about the cost-effectiveness of pneumococcal conjugate vaccination in older adults?A T NewallVaccine|March 18, 2018
Evolution over time in the cost-effectiveness of pneumococcal conjugate vaccine (PCV13) in older Australians due to herd protection from infant vaccinationC Chen, P Beutels, A T NewallPharmacoeconomics|May 6, 2014
Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccinesA T Newall, M Jit, R HutubessyEpidemiology and Infection|November 28, 2009
Influenza-attributable mortality in Australians aged more than 50 years: a comparison of different modelling approachesA T Newall, C Viboud, J G WoodEpidemiology and Infection|September 20, 2014
Revisiting Styblo's law: could mathematical models aid in estimating incidence from prevalence data?M Begun, A T Newall, G B Marks, et al.Human Vaccines & Immunotherapeutics|May 2, 2015
A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderlyS Dirmesropian, J G Wood, C R MacIntyre, et al.Vaccine|August 28, 2018
Within-season influenza vaccine waning suggests potential net benefits to delayed vaccination in older adults in the United StatesA T Newall, C Chen, J G Wood, et al.Epidemiology and Infection|November 22, 2008
The burden of rotavirus gastroenteritis in children presenting to a paediatric hospitalE Inglis, A Kesson, A T Newall, et al.Epidemiology and Infection|May 8, 2019
Estimating seasonal variation in Australian pertussis notifications from 1991 to 2016: evidence of spring to summer peaksR N F Leong, J G Wood, R M Turner, et al.Vaccine|December 4, 2013
Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analysesA T Newall, J F Reyes, J G Wood, et al.Pageof 3